Zylo Therapeutics, Inc.
Zylö Therapeutics is dedicated to enhancing drug delivery through innovative encapsulation technologies, specifically utilizing their proprietary Z-pods®. Their mission is to improve product performance across various market segments by increasing bioavailability, stability, and targeted delivery of therapeutic compounds.
Industries
Nr. of Employees
small (1-50)
Zylo Therapeutics, Inc.
Greenville, South Carolina, United States, North America
Products
Amorphous silica particle delivery platform
A particle-based delivery platform composed of engineered amorphous silica particles designed to encapsulate diverse payloads to improve stability, solubility, bioavailability, and enable targeted or sustained local delivery (including sustained nitric-oxide release).
Amorphous silica particle delivery platform
A particle-based delivery platform composed of engineered amorphous silica particles designed to encapsulate diverse payloads to improve stability, solubility, bioavailability, and enable targeted or sustained local delivery (including sustained nitric-oxide release).
Services
Collaborative formulation and delivery development
Co-development of particle-encapsulated formulations for improved stability, solubility, bioavailability, or targeted topical delivery for pharma, OTC, cosmetic, and animal-health applications.
Preclinical efficacy testing and IND-enabling support
Design and execution of preclinical animal studies and associated activities intended to support IND-enabling packages and early clinical translation.
Manufacturing scale-up and quality system support
Scale-up of particle formulation manufacturing with implementation of ISO-9001-aligned quality management practices and cGMP-ready processes to support clinical supply.
Collaborative formulation and delivery development
Co-development of particle-encapsulated formulations for improved stability, solubility, bioavailability, or targeted topical delivery for pharma, OTC, cosmetic, and animal-health applications.
Preclinical efficacy testing and IND-enabling support
Design and execution of preclinical animal studies and associated activities intended to support IND-enabling packages and early clinical translation.
Manufacturing scale-up and quality system support
Scale-up of particle formulation manufacturing with implementation of ISO-9001-aligned quality management practices and cGMP-ready processes to support clinical supply.
Expertise Areas
- Nanoparticle-based drug delivery
- Topical and transdermal formulation development
- Nitric oxide-releasing therapeutic systems
- Solubility enhancement and formulation optimization
Key Technologies
- Amorphous silica nanoparticle/microparticle encapsulation
- Nitric oxide-releasing particle systems
- Sustained-release delivery technologies
- Topical/transdermal nanoparticle delivery